Proteasome inhibitor (PI)-based induction and consolidation proved to be effective in newly diagnosed multiple myeloma (NDMM) patients (pts) eligible for melphalan 200 mg/m2-autologous stem cell transplant (MEL200-ASCT). High response rates have been reported with the second-generation PI Carfilzomib in combination with Lenalidomide-dexamethasone (KRd) or Cyclophosphamide-dexamethasone (KCd). 

Rates of MRD negativity, sCR, ≥CR, ≥VGPR were significantly higher with KRd-ASCT-KRd and KRd12 vs KCd. At present, no differences in MRD and overall best response (sCR, ≥CR, ≥VGPR) were noticed between KRd-ASCT-KRd and KRd12; longer follow-up is needed to evaluate survival. Treatment was well tolerated. Updated data will be presented at the meeting.

Authors:

Francesca Gay, MD, Chiara Cerrato, MD, Delia Rota Scalabrini, MD, Monica Galli, MD, Angelo Belotti, MD, Elena Zamagni, MD, Antonio Ledda, MD, Mariella Grasso, MD, Emanuele Angelucci, MD, Anna Marina Liberati, MD, Patrizia Tosi, MD, Francesco Pisani, MD, Stefano Spada, Ombretta Annibali, MD, Anna Baraldi, MD, Paola Omedé, Piero Galieni, MD, Rita Rizzi, MD, Norbert Pescosta, MD, Sonia Ronconi, MD, Donatella Vincelli, MD, Anna Maria Cafro, MD, Massimo Offidani, MD, Antonio Palumbo, MD, Pellegrino Musto, MD, Michele Cavo, MD and Mario Boccadoro, MD


121 Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs Krd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-Kcd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)


ABOUT FRANCESCA GAY, MD, PhD

Dr. Francesca Gay is a hematologist at the Myeloma Unit, Division of Hematology, Azienda Ospedaliero Università Città della Salute e della Scienza, in Torino, Italy. She completed her medical degree in 2004 and her fellowship in hematology in 2008 at the University of Torino, Italy. She obtained her PhD in Medicine and Experimental Therapy in 2014. She focuses on multiple myeloma and associated disorders, as well as helps the design and development of myeloma clinical trials. Her papers have been published in peer-reviewed journals, and she has been a reviewer for medical journals including Leukemia and Haematologica.

 

Previous Post
Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs
Next Post
Preliminary Results from a Phase I Study of Isatuximab in Combination with Bortezomib, Lenalidomide, Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplant

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.